Treatment of hypertension with captopril: preservation of regional blood flow and reduced platelet aggregation
James, I.M.; Dickenson, E.J.; Burgoyne, W.; Jeremy, J.Y.; Barradas, M.A.; Mikhailidis, D.P.; Dandona, P.
Journal of Human Hypertension 2(1): 21-25
1988
ISSN/ISBN: 0950-9240 PMID: 3070031 Document Number: 313098
The BP of 12 patients with essential hypertension was controlled with captopril over a period of three months. Cerebral blood flow, muscle blood flow (anterior tibialis muscle), platelet aggregation and platelet thromboxane A2 release were measured during a baseline drug-free period, and measurements repeated during the treatment phase on achieving BP control, after one and three months. Cerebral blood flow rose during the early phase of treatment and then dropped to baseline levels during chronic therapy. Muscle blood flow, both at rest and following maximal exercise, was unaffected by captopril therapy. Platelet aggregation was diminished during therapy, and this finding was paralleled by a reduction in platelet thromboxane A2 generation. Control of hypertension with maintenance of regional blood flow and beneficial changes in platelet function during treatment with captopril may improve the overall risk profile of hypertensive patients. Inhibition of platelet aggregation and thromboxane A2 release may contribute to the antihypertensive action of captopril and the maintenance of regional blood flow.